Company Overview and News
New Zealand shares rose, led higher by a record profit from Skellerup Holdings, as investors focused more on domestic earnings than volatility in global markets. Precinct Properties New Zealand also gained.
CEN AIA FBU FCREY SPKKY NZTCY SPK NZTCF ACKDF FRCEF AUKNY COENY COENF AOTUF SKC AIA FBU CEN SKLUY SKL PFGTF SML
New Zealand shares bounced back from some of yesterday's sell-off as investors are yet to see serious contagion from Turkey's burgeoning financial crisis, led higher by Synlait Milk and A2 Milk Co. Summerset Group Holdings fell after reporting first-half earnings.
AIR FCREY NZTCF ACKDF ANZFY AUKNY AIZ SKT SYKWF SKKTY SNZ SML AIA FBU SPKKY NZTCY SPK FRCEF PGW KWIPF PGWFY AIA FBU ANZLY ANZFF PGWFF MEZ PFGTF
Pacific Edge said Manchester Management Company, a US privately-owned fund specialising in biotech and life sciences investments, will take a 1.7 per cent stake in the company, reflecting growing international investor interest.
The following slide deck was published by Pacific Edge Limited in conjunction with their 2018 Q4 earnings call.
New Zealand shares had a slight fall today, after a mixed bag of company results announcements.
Appetite among global fund managers for high-yielding New Zealand stocks has gone on pause for the last three to six months after two to three years of consistent monthly demand, the managing director of Harbour Asset Management, Andrew Bascand, says.
AIA FBU WBC RHCGF FCREY ZNRGF WEBNF RYM NZR WBK ACKDF FRCEF ZEL AUKNY SKT ZNZ SYKWF AIA WBC FBU RYHTY SKKTY PFGTF
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
2018-09-18 - Asif
Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...
2018-09-18 - Asif
Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...
as of ET